Clinical trial · Interventional
Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Evaluation of the Nutritional Supplement Oncoxin-Viusid® in the Treatment of 20 Patients With Cutaneous Melanoma in Stage IIB-IIIA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs. For this reason, a study with nutritional supplement Oncoxin-Viusid was carried out. According to previous studies, it has an antitumor, immunomodulatory effect and to potentiate the antiproliferative effect of standard chemotherapeutic agents in different locations and stages of cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous Melanoma, Stage II | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
| Cutaneous Melanoma, Stage III | Cutaneous Melanoma | CURATED_BROADER | 0.78 |
| Malignant Cutaneous Melanoma | Cutaneous Melanoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oncoxin-Viusid | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Oncoxin-Viusid
- description
- Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
- interventionNames
- Dietary Supplement: Oncoxin-Viusid
Primary outcomes (2)
- measure
- Overall survival rate
- timeFrame
- 2 years
- description
- Calculated according to the method of Kaplan Meyer
- measure
- Disease free survival rate
- timeFrame
- 2 years
- description
- Calculated according to the Kaplan Meyer method
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histological diagnosis of Malignant Cutaneous Melanoma in stage IIB-IIC-IIIA * Subjects of 18 years and over of both sexes. * General health status according to the Karnofsky Index ≥ 70. * Laboratory parameters within the normal limits defined as: Hematopoietic: Hemoglobin ≥ 9 g / L, Total Leukocytes ≥ 3 x 109 cells / L, Neutrophils ≥ 1.5 x 109 cells / L, Platelets ≥ 100 x 109 / L Hepatic: Liver function within 2.5 times upper normal limit and without liver disease demonstrated by TGP, OGT and alkaline phosphatase. * Patients who express written voluntariness to enter the study with their signature of the informed consent document. * Women of childbearing age should have a negative pregnancy test and use effective contraceptive methods such as intrauterine devices, hormonal contraceptives, barrier method or tubal ligation. Exclusion Criteria: * Pregnancy or lactation. * Patients with a second concomitant tumor. * Present an associated chronic disease in the decompensation phase (heart disease, diabetes, hypertension). * History of hypersensitivity to another similar product. * Severe acute allergic states. * Severe septic processes. * Non-operated patients, in whom the surgery was contraindicated. * Patients at potential risk of not completing the study (those who will travel during the period of the investigation or distance in their residence, outside the city). * Subjects who are participating in another clinical trial. * Patients with cognitive disorders or a mental disorder that hinders their follow-up.
References
Publications (0)
Data not yet available